Comparison of Lipid-Modifying Efficacy of Rosuvastatin Versus Atorvastatin in Patients With Acute Coronary Syndrome (from the LUNAR Study)
| Autor: | Joseph Loscalzo, Bertram Pitt, Elinor Miller, Joel S. Raichlen, John T. Monyak |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male medicine.medical_specialty Acute coronary syndrome Atorvastatin Blood lipids Drug Administration Schedule Coronary artery disease Electrocardiography Young Adult chemistry.chemical_compound Internal medicine medicine Humans Pyrroles Rosuvastatin Prospective Studies Acute Coronary Syndrome Rosuvastatin Calcium Aged Sulfonamides Dose-Response Relationship Drug Cholesterol business.industry nutritional and metabolic diseases Cholesterol LDL Middle Aged medicine.disease United States Fluorobenzenes Survival Rate Pyrimidines Treatment Outcome chemistry Heptanoic Acids Cardiology Female lipids (amino acids peptides and proteins) Hydroxymethylglutaryl-CoA Reductase Inhibitors Cardiology and Cardiovascular Medicine business Follow-Up Studies medicine.drug Lipoprotein |
| Zdroj: | The American Journal of Cardiology. 109:1239-1246 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2011.12.015 |
| Popis: | Patients with acute coronary syndrome are recommended for early aggressive low-density lipoprotein (LDL) cholesterol-lowering therapy. The LUNAR study compared the efficacy of rosuvastatin with that of atorvastatin in decreasing LDL cholesterol in patients with acute coronary syndrome. Adult patients with coronary artery disease who were hospitalized for an acute coronary syndrome within 48 hours of first symptoms were randomized (n = 825) to an open-label, once-daily treatment with rosuvastatin 20 mg (RSV20), rosuvastatin 40 mg (RSV40), or atorvastatin 80 mg (ATV80) for 12 weeks. Patients were evaluated at weeks 2, 6, and 12. The primary end point was treatment efficacy in lowering LDL cholesterol averaged over 6 to 12 weeks. Changes in other lipoproteins, including high-density lipoprotein (HDL) cholesterol, and safety were evaluated. Analysis of covariance was used to compare least squares mean differences between each rosuvastatin treatment arm and the atorvastatin arm. The efficacy of RSV40 in lowering LDL cholesterol was significantly greater than that of ATV80 (46.8% vs 42.7% decrease, p = 0.02). LDL cholesterol lowering by RSV20 was similar to that by ATV80. Increases in HDL cholesterol were significantly greater with RSV40 (11.9%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect